Genetic clues to cisplatin-related hearing toxicity remain uncertain
A review found genetic associations with cisplatin-related hearing toxicity, but inconsistent results limit their value for predicting individual risk.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
This review examined whether variation in DNA repair genes could help predict cisplatin-related hearing toxicity. Some genetic patterns were associated with lower odds of toxicity, while certain combinations were associated with higher odds. The overall evidence remained inconsistent, so the abstract does not establish a dependable genetic test for identifying patients at higher risk.
The abstract does not specify reference genotypes, toxicity assessment timing or performance of a prediction test. The authors also describe limited coverage of populations and genetic variants.
Genetic patterns differed
An XPC variant was linked with lower odds of toxicity in a particular genotype grouping, while combinations involving that variant and other genes were linked with higher odds. These contrasting patterns do not establish a reliable prediction tool.
Association is only part of prediction
The review asked whether genetic differences could explain susceptibility to hearing toxicity during cisplatin treatment. It does not report how accurately a genetic test identified future cases, leaving its practical predictive usefulness unresolved.
The original publication
The association between DNA repair genes polymorphisms and cisplatin-induced ototoxicity in cancer patients: a systematic review.
Omar NE, Mekkawi R, Said S et al.
Per Med · 2025
- PubMed ID
- 41532599
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.